Director at Interpace Biosciences
Edward Chan was appointed to the Board effective January 15, 2020. Mr. Chan has over 12 years of experience in healthcare investing. Since 2016, Mr. Chan has been a principal at 1315 Capital, a Philadelphia-based firm that provides expansion and growth capital to healthcare companies. Prior to 1315 Capital, Mr. Chan was a vice president at NaviMed Capital, a lower middle-market healthcare investment firm and an associate at Siemens Venture Capital, the investment arm of Siemens. Edward started his career developing and commercializing a molecular diagnostic product at a venture backed company. Mr. Chan has been involved in several diagnostics and biopharma services investments including China Diagnostics Medical Corporation (acquired by Actis Capital), BioImagene (acquired by Roche), RadPharm (acquired by JLL Partners), Cylex (acquired by Viracor-IBT), Sequenom (acquired by LabCorp) and Genoptix (acquired by NeoGenomics). He currently serves on the board of Centurion Service Group. Mr. Chan received a BSc in Biomedical Engineering from Johns Hopkins University and an MBA from the Wharton School at the University of Pennsylvania.